HIGHLIGHTS
- who: Xiang Zhou and colleagues from the Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany have published the research work: Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease, in the Journal: Cancers 2020, x of /2020/
- what: This study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD.
- how: The authors analyzed ORR clinical benefit rate (CBR) overall survival (OS) and progression-free survival (PFS) following the current criteria of the International Myeloma Working Group (IMWG . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.